US Stock MarketDetailed Quotes
CMMB Chemomab Therapeutics
- 1.150
- +0.030+2.68%
Trading Jul 22 14:50 ET
16.35MMarket Cap-746P/E (TTM)
1.180High1.110Low31.96KVolume1.150Open1.120Pre Close36.88KTurnover0.34%Turnover RatioLossP/E (Static)14.22MShares1.37552wk High1.23P/B10.82MFloat Cap0.42052wk Low--Dividend TTM9.41MShs Float184.000Historical High--Div YieldTTM6.25%Amplitude0.420Historical Low1.154Avg Price1Lot Size
Chemomab Therapeutics Stock Forum
Sign in to post a comment
$Chemomab Therapeutics(CMMB.US$ 90%+ of todays volume has come in the last 15 minutes! And so far 35K+ more buys than sells and it’s hardly moved! Hehehe
1
1
$Chemomab Therapeutics(CMMB.US$ Benzinga· 1 min ago
CHEMOMAB Granted U.S. Patent #12018074: Anti CCL24 (Eotaxin2) Antibodies for Use in the Treatment of Hepatic Diseases
CHEMOMAB Granted U.S. Patent #12018074: Anti CCL24 (Eotaxin2) Antibodies for Use in the Treatment of Hepatic Diseases
1
$Chemomab Therapeutics(CMMB.US$ Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its Ccl24-Neutralizing Antibody Cm-101 in Primary Sclerosing Cholangitis
$Chemomab Therapeutics(CMMB.US$ Im still bullish and look forward to the PHASE 2 Topline data readout! NFA Just thinking outloud![]()
TEL AVIV, Israel, June 06, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported that it presented two scientific posters supporting the clin...
TEL AVIV, Israel, June 06, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported that it presented two scientific posters supporting the clin...
$Chemomab Therapeutics(CMMB.US$ Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update ─On Track for Midyear 2024 Topline Data and Late 2024/Early 2025 Open Label Data Readouts from CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis (PSC), Following Early Completion of Patient Enrollment Six Months Ahead of Schedule─ ─New Peer-Reviewed Publications Based on Patient Sample Studies Further Reinforce the Key Role of Chemomab’s Novel ...
1
$Chemomab Therapeutics(CMMB.US$ Chemomab Therapeutics Granted 180-Day Extension By Nasdaq To Regain Compliance With Minimum Bid Price Rule
1
$Chemomab Therapeutics(CMMB.US$ Chemomab Reports New Peer-Reviewed Publication Reinforcing The Clinical Association Of Its CCL24 Target With Disease Severity and Mortality In Systemic Sclerosis
1
Breakthrough in Liver Disease Treatment: Chemomab's CM-101 Secures New European Patent.
In the realm of medical science, groundbreaking advancements often mark pivotal moments in the fight against debilitating diseases. One such recent development in the battle against Primary Sclerosing Cholangitis (PSC), a rare and potentially fatal liver disease, has emerged from the labs of Chemomab Therapeutics. The company has been...
In the realm of medical science, groundbreaking advancements often mark pivotal moments in the fight against debilitating diseases. One such recent development in the battle against Primary Sclerosing Cholangitis (PSC), a rare and potentially fatal liver disease, has emerged from the labs of Chemomab Therapeutics. The company has been...
$Chemomab Therapeutics(CMMB.US$ Waiting for the rest of the numbers! (((((. Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.26) per share. This is a 63.89 percent increase over losses of $(0.72) per share from the same period last year. )))))![]()
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Jaguar8 : Super